New pharmacogenomic paradigm in breast cancer treatment.
Offit
Kenneth
K
Robson
Mark E
ME
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D047072:Aromatase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D004967:Estrogens / Q000378:metabolism*; D005260:Female; D006801:Humans; D016017:Odds Ratio; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D012107:Research Design
D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D004967:Estrogens; D011518:Proto-Oncogene Proteins; C090851:TCL1A protein, human